• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
MYGN

MYGN

Myriad Genetics, Inc.

NASDAQHealthcareMedical - Diagnostics & ResearchUS

USD4.31

+0.03 (+0.70%)

Rating:C-

Company Profile

CEO

Samraat S. Raha

IPO Date

1995-10-06

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Exchange

NASDAQ

Country

US

Market Metrics

Open

$4.22

Prev. Close

$4.28

Day Low

$4.12

Day High

$4.45

52W Low

$3.53

52W High

$8.59

Market Cap

$0.41B

Volume

2.38M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

36.7%

Avg Negative

4.4%

Avg Neutral

58.8%

News Feed

New research reveals most Americans can't identify the symptoms of depression

GlobeNewsWire·7/28/2021·↓ negative

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

GlobeNewsWire·7/21/2021·↑ positive

Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units

Zacks Investment Research
·7/2/2021
·↑ positive

Myriad Genetics Completes Sale of Myriad RBM to IQVIA's Q2 Solutions

GlobeNewsWire·7/1/2021·↑ positive

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

GlobeNewsWire·6/16/2021·↑ positive

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

GlobeNewsWire·6/4/2021·↑ positive

Myriad Genetics (MYGN) Sells myPath to Focus on Core Units

Zacks Investment Research·6/2/2021·↑ positive

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

GlobeNewsWire·6/1/2021·↑ positive

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

Zacks Investment Research·5/31/2021·↑ positive

IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

PRNewsWire·5/27/2021·↑ positive